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ABSTRACT 
Objective: Formulation and development of delayed release mini tablets in the capsule of drug lenalidomidein terms of dissolution and stability 
was the objective of the present work. 
Methods: Tablets of less than or equal to 3 millimetres diameter are Mini-tablets, which were filled into a capsule. Direct compression method using multi-
tip punch was used for compression and coated with eudragit L100 as a seal coating material and with eudragit L30D55 as an enteric coating material was 
done. Different formulations were prepared and subjected for evaluation like weight variation, hardness, friability, disintegration, and dissolution studies. 
The optimized formulation was compared to marketed product based on drug released profile and also subjected for stability studies.  
Results: The results revealed that the in vitro drug release of prepared formulations, F1, F2, F3, and F4 was subjected for acid resistance test for 2 h 
in 0.1N HCl and has a comparable dissolution profile in phosphate buffer of 6.8 pH. FormulationF4 was subjected for stability studies and no 
significant difference was observed in 3 mo 40 °C/75% RH accelerated stability condition. 
Conclusion: The dissolution profile of formulation F4 was found better than that of market product. Based on evaluation results, the study 
concluded that F4formulationwas considered as an optimized formulation. 
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The aim of any dosage form was to release the effective and precise 
amount of drug at the target site to give a desired pharmacological 
response. Delayed release system are systems used for repetitive 
and intermittent dosing of a drug from multiple immediate release 
units that is merged into a single dosage form [1]. Mini tablets are 
slightly curved or flat tablets which have diameter ranged between 
1.0-3.0 millimeters; they can thus be filled into capsules. Mini tablets 
can be compressed into larger tablets, and occasional it can be filled 
in sachets for easy administration [2]. The drug release can be 
achieved due to increase surface in relationship with volume of drug. 
The rationale of mini tablets formulation is to accomplish several 
releases in one formulation by combining altered dose. Passage of 
mini tablets through the stomach is better than normal tablets due 
to their small dimension. Due to this, mini tablets are formulated in 
the study to achieve the desired drug concentration in plasma is 
achieved [3]. 
Formulation of one capsule containing different mini tablets, each 
developed independently and designed to release at the different 
site of the gastrointestinal tract can be achieved. Mini tablets have 
the merit of achieving multi-particulate dosage forms with the 
conventional manufacturing systems of tableting [4]. A further 
advantage of mini tablets includes their uniformity in size, shape, 
and surface, thereby offering an exceptional well substrate for 
coating with modified release polymeric systems [5]. 
When the capsule disintegrates, mini-tablets inside the capsule 
release and distribute throughout the gastrointestinal tract. The 
subunits act as self-contained depots, which makes it possible for the 
division of multiple unit tablets with no loss in depot effect. Mini 
tablets represent total subunits present in the capsules. The 
therapeutic effect of the capsule is directly related to the 
functionality of each mini tablet in the capsule [6]. 
Thalidomide on chemical modification yields lenalidomide. This 
potent analogue has decreased neurological effects such as sedation 
and neuropathy as compared to parent molecule. It shows an effect 
against haematological and solid malignancies. Lenalidomine being 
immunomodulatory shows the effect on the immune system at both 
cellular and humoral limbs. It also exhibits anti-angiogenic action. 
The novelty of the study lies in formulation and development of 
delayed release mini tablets in the capsule of drug lenalidomide. The 
drug was chosen with the aim to reduce the side effects of 
thalidomide and improve the increases the efficacy [7]. 
MATERIALS AND METHODS 
Materials 
Lenalidomide was obtained as a sample from Sigma Alrich Pvt. Ltd, 
Mumbai, India, along with triethyl citrate. Microcrystalline cellulose, 
silicified microcrystalline cellulose, magnesium stereate, and talc 
was procured from Loba Chemie Pvt. Ltd. croscarmellose sodium, 
silica colloidal silicon dioxide and type a methacrylic acid copolymer 
dispersion was procured from Merck Pvt. Ltd. 
 
Table 1: List of equipment and instruments 
S. No. Name Manufacturer 
1. Blender Ganson Engineers Private Limited 
2. Tablet Compression machine Cadmach machine Co. PVT LTD 
3. Tablet Coating machine Gansons Limited 
4. Digital weighing balance Shimadzu 
5. Hardness tester Monsanto 
6. Disintegration test apparatus Electro lab 
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Fourier transform infra-red (FT-IR) spectrum 
A Fourier Transform Infrared (FTIR) spectrum was carried out to 
check the chemical compatibility of Drug and Excipient by Shimadzu 
8400S FTIR (Tokyo, Japan) by KBr pellet press method. The 
Spectrum was recorded over the range 40-4 m-1
Was done by weighing required quantity of eudragit L 100, 
isopropyl alcohol and triethylcitrate (TEC). In lenalidomide, steadily 
add triethyl citrate and mixing for 10 min was done. Then eudragit L 
100 was added to the above solution. Stirred for one and a half hours 
until a clear solution was formed [10, 11]. Then seal coating was 
carried out on compressed core mini tablets. The enteric coating was 
done by eudragit L30D55 solution. 
[8]. 
Preparation procedure 
The preparation was carried out after obtaining all the ingredients. 
Sifting was done by co-sifting API, Microcrystalline cellulose, Silica 
colloidal silicon dioxide, and Acdisol, Aerosil, through sieve #40. The 
sifted granules were mixed in a blender for 20 min at 15 rotations 
per min to achieve uniform blending. The lubrication was done by 
using Magnesium stearate. Compression of the tablet was done using 
a double rotatory compression machine using 2 millimeters 
diameter standard concave plain punch [9]. Seal coating was done 
by using eudragit L 100 solution.  
Preparation of eudragit L100 solution 
Preparation of eudragit L30D55 solution 
Was done by, weighing required quantity of Purified Water, talc, 
TEC, eudragit L30 D55, in water, TEC was gradually added. Talc was 
diversified for 15 min followed by addition of dimethicon. In the 
above solution Eudragit L30D55 was slowly added, with continuous 
stirring for thirty minutes. Then enteric coating was performed on 
seal coated mini tablets [12, 13]. Capsule filling and Packing was 
done in the next step; the drug product was intended to be labelled 
for storage at 15 °-30 °C [14, 15]. 
All the other ingredients were kept constant and the concentration of 
eudragit L30D55 as enteric coating and eudragit L100 as seal coating 
were changed for different formulations from F1 to F4 (table 2). 
Post-compression and coating parameters 
Evaluation of mini tablets was done for parameters like weight 
variation, hardness, thickness, and disintegration and tabletting 
issues such as capping, sticking. The mini-tablets were inspected for 
shape, colour and other tablet defects by keeping the tablets in light. 
Uniformity of weight and drug content, as per I. P was also 
determined. Friability was measured using electrolabfriabilator. 
Hardness tester was used to determine the hardness. 
 
Table 2: Formulation chart for mini tablets compression and coating 
S. No. Ingredients Qty/Tab (mg) 
Core Tablet 
F1 F2 F3 F4 
1 Lenalidomide 3.038 3.038 3.038 3.038 
2 Avicel 200 0.700 0.700 0.700 0.700 
3 Prosol SMCC 90 1.722 1.722 1.722 1.722 
4 Crosscarmellose sodium 0.360 0.360 0.360 0.360 
5 Aerosil 200 0.060 0.060 0.060 0.060 
6 Magnesium Stearate 0.120 0.120 0.120 0.120 
Total weight of core tablets (mg) 6.000 6.000 6.000 6.000 
Seal Coating 5.00% 5.00% 3.50% 3.50% 
1 Eudragit L 100 0.180 0.180 0.126 0.126 
2 Triethyl citrate 0.120 0.120 0.084 0.086 
3 IPA q. s. q. s. q. s. q. s. 
Total weight of seal coated tablets (mg) 6.300 6.300 6.210 6.210 
Enteric Coating 25% 20% 20% 25% 
1 Eudragit L 30D55(Solid) 0.742 0.594 0.585 0.731 
2 Triethyl citrate 0.742 0.594 0.585 0.731 
3 Talc 0.082 0.066 0.065 0.081 
4 Dimethicon 0.009 0.007 0.007 0.009 
5 Purified Water q. s. q. s. q. s. q. s 
Total weight of Enteric coated tablets (mg) 7.875 7.560 7.450 7.760 
 
Weight variation 
Initially, 20 units of pellets were randomly selected which was 
weighed individually and the average was calculated. Weight 
variation was carried out by using digital balance [16]. The digital 
weighing balance model used to calculate weight variation is 
shimadzu (model no. BL 220H). The percentage deviation in weight 
was calculated by:  




In this, 10 tablets were assessed for thickness by using an electronic 
vernier caliper, Mitutoyo, Japan. 
Hardness 
Monsanto hardness tester was employed to evaluate the hardness of 
randomly selected mini tablets [16]. 
Disintegration 
The disintegration of the capsule was examined by electro lab 
disintegration tester (USP) ED–2AL for 15 min. 
Dissolution 
The apparatus used for dissolution is electro lab TDT USL. Lenalidomide 
has high solubility across the physiological pH range. For carrying out 
dissolution profiles studies of lenalidomide delayed-release capsule, USP 
apparatus II was employed at 100 rotations per min with 0.1 N HCl for 
first two hours and later at pH 6.8 phosphate buffer [17]. 
Stability studies 
Stability studies were carried out by storage of tablets in containers 
inside thermolab S. S. 304 and analysed at regular intervals for different 
parameters like appearance, assay of API, determination of degradation 
products, dissolution time etc.; Stability studies were conducted at 
following conditions. Storage conditions: 40 °C±2 °C/75% RH±5% RH, 
25 °C±2 °C/60% RH±5% RH for the period of 1 and 3 mo [18]. 
RESULTS AND DISCUSSION 
Preformulation studies 
Drug-excipient compatibility studies were examined using FTIR. The 
following graph was obtained (fig. 1). The drug and excipient were 
found to be compatible. 
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Fig. 1: FTIR of pure drug and physical mixture 
 
Post-compression and coating parameters 
Prepared tablets were evaluated during the process for weight 
variation, hardness, thickness, disintegration and tab letting issues 
such as capping, sticking, coating and results are tabulated in table 4. 
Dissolution studies 
Dissolution studies were carried out by using 0.1N HCl buffer 
followed by 6.8 pH buffer, and the results are depicted in table 5. 
The dissolution varied for all the formulation, the desired 
dissolution profile on comparison was achieved by formulation F4. 
The results obtained indicate that F4 meets all the in process 
parameters and hence, increased concentration of eudragit L30D55 
of 25% has shown an increase in the drug release. 
According to Umesh N Et al. Mini particulate formulation coated with 
eudragit were targeted to release the drug in the intestine. A similar 
observation was made in the dissolution profile of the present study, 
wherein the drug showed no release in the acidic medium but 
exhibited 89.12-95.91 % release in the intestinal pH [19]. 
The comparative dissolution profile of the marketed product 
and lenalidomide DR capsule:  
The Prepared lenalidomide DR capsules have shown more 
percentage of drug release than the available marketed formulation 
and the values are as shown in table 6. 
Stability studies 
The stability studies for lenalidomidedelayed release mini 
tablets in capsules was carried out for optimized formulation. In 
accordance to ICH guidelines, stability studies were carried out 
by storing at 25 °C/ 60% RH and 40 °C/75% RH for 1 and 3 mo 
was carried out for the optimized formulation. The samples were 
analysed and checked for changes in physical appearance and 
release profile at 1st and 3rd
 
 month, and the results are tabulated 
in table 7. 
Table 4: Post-compression and coating parameters 
Formulations F1 F2 F3 F4 
Test CT ECT CT ECT CT ECT CT ECT 
Average weight (mg) 6.03±0.17 7.88±0.11 6.05±0.23 7.5±0.12 6.15±0.34 7.42±0.15 6.09±0.23 7.74±0.11 
Hardness (N) 18.5±0.25 24.61±0.23 17.18±0.42 24.11±0.15 19.53±0.38 23.43±0.24 19.33±0.21 24.53±0.17 
Thickness (mm) 1.85±0.09 2.05±0.13 1.83±0.21 2.12±0.53 1.79±0.28 1.97±0.13 1.85±0.17 1.95±0.11 
Disintegration (min) 
at pH 6.8 buffer 
- 15 - 15 - <15 - <10 
Capping 
Lamination and Sticking 
Nil Nil Nil Nil Nil Nil Nil Nil 
mean±SD, n = 3, CT= Core tablet; ECT= Enteric Coated Tablet 
 
Table 5: Dissolution profile of the drug 
Time (min) % Drug release 
0.1N Hcl buffer 
Formulations F1 F2 F3 F4 
120 2.09±0.27 1.25±0.44 2.31±0.45 1.02±0.37 
6.8 pH Phosphate buffer 
5 44.32±0.37 53.81±0.54 54.32±0.48 37.51±0.21 
10 73.3±0.51 83.7±0.24 84.4±0.24 93.21±0.24 
15 89.12±0.24 91.2±0.57 93.4±0.28 95.91±0.15 
mean±SD, n = 3 
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Table 6: Comparative dissolution profile of the marketed product and lenalidomide DR capsule 
Time (min) % Drug released of a marketed product % Drug released of lenalidomide capsule 
0 0 0 
10 94.06±0.33 93.21±0.24 
15 95.21±0.18 95.91±0.15 
30 96.72±0.15 97.2±0.31 
45 97.5±0.52 98.14±0.29 
mean±SD, n = 3 
 
Table 7: Stability studies 
Condition and 
month 
Initial 25 °C/60% RH (1-
M) 
40 °C/7 5% RH 
(1-M) 
25 °C/60 % RH 
(3-M) 
30 °C/65 % RH 
(3-M) 
40 °C/7 5% RH 
(3-M) 
Dissolutiona 
Time preformed % Drug release 
120 min (0.1 N 
HCl) 
1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 
pH 6.8 Phosphate buffer 
10 min 93.54±0.31 95.13±0.47 93.63±0.37 94.32±0.19 89.43±0.29 89.12±0.21 
15 min 94.42±0.53 95.43±0.42 95.65±0.54 94.22±0.47 94.29±0.39 93.13±0.91 
30 min 95.91±0.54 95.57±0.45 95.31±0.29 95.12±0.37 94.42±0.37 93.91±0.37 
45 min 97.42±0.42 97.54±0.24 97.82±0.65 98.43±0.18 95.21±0.82 94.32±0.44 
mean±SD, n = 3, There was no significant difference observed under 25 °C and 60% RH and 40 °C and 75% RH accelerated stability condition at the 




The delayed release of mini tablets in the capsule of lenalidomide 
was developed. The drug lenalidomide is found to have better in 
vitro drug release in mini-tablets form than the conventional dosage 
form. However, further clinical trials are necessary to ensure the 
improved efficacy and safety of lenalidomide mini tablets. 
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